• More
    FAQs
    Download Lutasun profile
    Contact us
    Site Map

  • Lutasun-首页-焦点图1

  • Lutasun-首页-焦点图2

  • About Lutasun
  • Mechanism of Action
  • Clinical Application
  • About liver disease
  • FAQs
  • Lutasun, as an adjunct treatment of liver diseases

    Emma:Acute viral hepatitis A. Clinical symptoms: hypodynamia, appetite loss, distension, hepatalgia; Physical sign: hepatomegaly with tenderness; Chemical test: ALT, AST, TBIL increased significantly; Etiological diagnosis: HAV-RNA existing in serum.

    Analysis: Viral hepatitis led to primary liver injury, which cannot be cured just by antiviral therapy.

    Treatment: Reduced glutathione was administered in conjunction with routine treatment. After 4 weeks, Emma’s clinical symptoms and physical sign improved remarkably. ALT, AST, TBIL decreased to normal ranges.

  • Lutasun, as an adjunct treatment of chemotherapy on tumor

    Peter: Gastrointestinal carcinoma. After systemic chemotherapy for one week, severe side effects occurred, including abnormal liver function, nausea, vomiting, etc. Chemotherapy was suspended.

    Analysis: More often than not, drugs for chemotherapy have severe toxic effects on liver, neuron, etc.. A significant portion of patients undergoing chemotherapy have to discontinue the treatment because they cannot tolerate the side effects.

    Treatment: Reduced glutathione was administered after suspension of the chemotherapy. Two weeks later, liver function improved significantly. Peter continued to undergo chemotherapy.

Home|Legal Statement|Privacy Policy|Contact US|Sitemap

Copyright :copyright: YAOPHARMA All Rights Reserved 渝ICP备11001460号-12

Affliates Link

  • yaopharma
  • lutasun
  • fosunpharma
  • carelife
  • hexinpharma

Download Lutasun profile